A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients

BACKGROUND: Activation of the vascular endothelial growth factor receptor (VEGFR) and the oncogenic Src pathway has been implicated in the development of castration-resistant prostate cancer (CRPC) in preclinical models. Cediranib and dasatinib are multi-kinase inhibitors targeting VEGFR and Src res...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Invest New Drugs
Päätekijät: Spreafico, Anna, Chi, Kim N., Sridhar, Srikala S., Smith, David C., Carducci, Michael A., Kavsak, Peter, Wong, Tracy S., Wang, Lisa, Ivy, S. Percy, Mukherjee, Som Dave, Kollmannsberger, Christian K., Sukhai, Mahadeo A., Takebe, Naoko, Kamel-Reid, Suzanne, Siu, Lillian L., Hotte, Sebastien J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4281773/
https://ncbi.nlm.nih.gov/pubmed/24788563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0106-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia